Category: AT-527

Shots:

Chugai gets exclusive development and commercializing rights for AT-527 in Japan
Earlier, Roche and Atea collaborated to jointly develop AT-527. If approved, Atea to distribute AT-527 in the US and Roche will be responsible for global manufacturing and distribution outside the US
AT-527 is an investigational, oral, purine nucleotide prodrug, currently being evaluated in a P-II study in patients with moderate COVID-19 requiring hospitalization and patients with mild to mod. COVID-19 who are not hospitalized. A P-III study is expected to start in the H1’21

Click here to read full press release/ article | Ref: Chugai | Image: Wikipedia

Shots:

The companies will collaborate to develop, manufacture, and distribute AT-527 to combat COVID-19. If approved, Atea will be responsible for distributing the treatment option in the US, with the option to request Genentech’s support, and Roche will be responsible for distribution outside the US
The therapy is currently being evaluated in P-II study for hospitalized patients with moderate COVID-19 with anticipated P-III initiation in Q1’21, that explores the potential use in patients outside of the hospital setting. Additionally, AT-527 may be developed for post-exposure prophylactic settings
AT-527 is an investigational, oral, purine nucleotide prodrug that has demonstrated in antiviral activity against several enveloped single-stranded RNA virus, including human flavivirus and coronavirus

Click here to read full press release/ article | Ref: Roche | Image: The Times of Israel